Dihydroetorphine hydrochloride, also known as dihydroetorphine hydrochloride sublingual tablets, is commonly prescribed in a single 20-40 mcg dose. Dihydroetorphine hydrochloride sublingual tablets, is limited to the use of trauma, post-surgery and diagnosis of a variety of severe pain pain relief, including the ineffectiveness of morphine or pethidine, the usual amount prescribed for each sublingual 20-40 micrograms, the maximum allowable amount of 60 micrograms / times, 180 micrograms a day, not more than 3 days of continuous use of the drug. Adverse effects of the drug include dizziness, nausea, vomiting, fatigue, sweating, etc. It is prohibited to use in patients with traumatic brain injury, delirium or pulmonary insufficiency, infants and young children, immature newborns, and patients with non-excruciating pains such as toothache, headache, rheumatism, hemorrhoids, or pain from small traumatic injuries to local tissues, as well as patients with hepatic and renal insufficiencies. This drug is a national special management of narcotic drugs, should be applied under the guidance of a physician, can not be swallowed, pay attention to the observation of the efficacy of the medication, if the effect is not good, go to the hospital in a timely manner, do not be negligent, in order to avoid delays in the condition.